



Axel-Rainer Hanauske, MD, Ph.D., MBA

PERSONAL DATA

Office Address: Senior Medical Fellow, Global Early Drug Development Lilly Oncology
Lilly Deutschland GmbH, Werner Reimers Str. 2-4, 61352 Bad Homburg
Business Phone: (+49) 172 323 6526/ (+49) 6172 273 2249
Business Fax: (+49) 6171 273 3507

EDUCATION

2007 Board Certification Palliative Care
2006 MBA
1992 Board Certification Hematology / Medical Oncology
1990 Board Certification for Internal Medicine
1990 ESMO Examination in Medical Oncology
1983 Visa Qualifying Examination
1980 Approbation
1980 ECFMG Examination
1972-1980 Medical School, Georg August Universität, Göttingen and
Justus Liebig Universität, Giessen
1964-1972 Wolfgang-Ernst Gymnasium, Büdingen

WORK EXPERIENCE

07.2014 – present Senior Medical Fellow, Global Early Drug Development Lilly Oncology, Eli Lilly & Co.
Indianapolis, IN, USA
09.2010 – 06.2014 Senior Medical Director and Vice President, Lilly Oncology Medical Europe,
Eli Lilly & Co., Indianapolis, IN, USA
07.2009 – 09.2010 Senior Medical Director, Eli Lilly & Co., Indianapolis, IN, USA
04.2008 – 07.2009 Global Brand Development Leader, Eli Lilly & Co., Indianapolis, IN, USA
12.2006 – 03.2006 Medical Leader Enzastaurin and Alimta, Eli Lilly & Co., Indianapolis, IN, USA
08.2006 – 11.2006 Chair, III. Department of Medicine, Asklepios Hospital St. Georg, Hamburg, Germany
04.2003 – 07.2006 Acting Chair, I. Department of Medicine,
Chief, Division of Medical Oncology
AK St. Georg, Hamburg, Germany
07.2001 – 05.2006 Vice-Chairman, Phase I/II Study Group,
Central European Society for Anticancer Research (CESAR)
07.2001– 03.2003 Chief, Division of Medical Oncology,
Deputy Chair, I. Department of Medicine,
AK St. Georg, Hamburg, Germany
01.1999-05.2001 Visiting Professor of Oncology, Catholic University Leuven,
Universitair Ziekenhuis, Gasthuisberg; Leuven, Belgium
12.1998 - present Professor of Medicine, Technical University; Munich, Germany
09.1991 – 05.2001 Associate Director, European Clinical Trials Institute for Drug Development
Cancer Therapy and Research Center; San Antonio, TX
01.2000 – 05.2001 Medical Director, Oncology New Drug Development Eli Lilly & Co., Indianapolis,
USA
01.1999 -01.2000 Director, Center for Hematology and Oncology; Munich, Germany
06.1996 – 06.1999 Board Member, European Organization for Research and Treatment of Cancer
(EORTC)
06.1996 – 06.1999 Chairman, EORTC Early Clinical Studies Group (ECSG)
06.1994 – 06.1999 Vice Chairman, Phase I / II Study Group of the AIO (Study Group for Medical
Oncology of the German Cancer Society)

Scientific Areas: Drug Development, Translational Research, Treatment Individualization
Publications: 195 Peer-reviewed publications
157 Review presentations
317 Poster/oral presentations